Nelotanserin

DRUG3 trials

Sponsors

Axovant Sciences Ltd.

Conditions

Dementia With Lewy BodiesLewy Body DementiaParkinson's Disease DementiaREM Sleep Behavior DisorderVisual Hallucinations

Phase 2

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

CompletedNCT02640729

Axovant Sciences Ltd.Lewy Body Dementia, Visual Hallucinations

Start: 2015-12-31End: 2017-11-30Updated: 2018-01-18

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

CompletedNCT02708186

Axovant Sciences Ltd.Dementia With Lewy Bodies, Parkinson's Disease Dementia, REM Sleep Behavior Disorder

Start: 2016-03-31End: 2018-05-31Updated: 2020-05-20

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

TerminatedNCT02871427

Axovant Sciences Ltd.Dementia With Lewy Bodies, Lewy Body Dementia, Parkinson's Disease Dementia +2

Start: 2016-10-20End: 2019-01-17Target: 80Updated: 2019-03-27

Related Papers

Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia

Sleep Medicine2021-02-2432 citations

[P3–027]: RESULTS OF A PHASE 2 STUDY OF NELOTANSERIN, A NOVEL 5HT2A RECEPTOR INVERSE AGONIST, IN LEWY BODY DEMENTIA SUBJECTS EXPERIENCING VISUAL HALLUCINATIONS

Alzheimer s & Dementia2017-07-01